Phase III EF-14 Trial Shows Tumor Treating Fields Improve OS in Brain Cancer

In season 4, episode 10 of Targeted Talks, Craig Horbinski, MD, PhD, reviews the clinical practice guidelines for central nervous system cancers.

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

MB-108 shows activity and is well tolerated in recurrent glioblastoma, with preclinical data supporting its combination with MB-101 CAR T-cell therapy for improved outcomes.

The FDA accepted the new drug application for TLX101-CDx and granted priority review to the agent in glioma.

The FDA has approved the Ion Torrent Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for treatment with vorasidenib.